Cargando…
Evaluation of Quality of Life at Progression in Patients with Soft Tissue Sarcoma
Introduction. Soft Tissue Sarcoma (STS) is a rare malignancy of mesodermal tissue, with international incidence estimates between 1.8 and 5 per 100,000 per year. Understanding quality of life (QoL) and the detrimental impact of disease progression is critical for long-term care and survival. Objecti...
Autores principales: | Hudgens, Stacie, Forsythe, Anna, Kontoudis, Ilias, D'Adamo, David, Bird, Ashley, Gelderblom, Hans |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Hindawi
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5420413/ https://www.ncbi.nlm.nih.gov/pubmed/28512389 http://dx.doi.org/10.1155/2017/2372135 |
Ejemplares similares
-
A Retrospective Analysis of Vinorelbine Chemotherapy for
Patients With Previously Treated Soft-Tissue Sarcomas
por: Anderson, Sibyl E., et al.
Publicado: (2006) -
Treatment Strategies for Metastatic Soft Tissue Sarcomas
por: Wiltink, Lisette M., et al.
Publicado: (2021) -
Quality of Life and Utility in Patients with Metastatic Soft Tissue and Bone Sarcoma: The Sarcoma Treatment and Burden of Illness in North America and Europe (SABINE) Study
por: Reichardt, Peter, et al.
Publicado: (2012) -
Soft Tissue Sarcoma of Lower Extremity: Functional Outcome and Quality of Life
por: Kask, Gilber, et al.
Publicado: (2021) -
Phase II Trial of Gemcitabine and Docetaxel with Bevacizumab in Soft Tissue Sarcoma
por: Dickson, Mark A., et al.
Publicado: (2015)